Verify genomic integrity with next-level detection using Genomic Proximity Mapping^TM (GPM)

Products used in human cell therapy require meticulous quality control to detect low-allele frequency structural variants (SVs) that may impact genomic integrity and the safety of cell therapy products.  The CytoTerra^® Cytogenetics Platform leverages the unique strengths of Genomic Proximity Mapping (GPM) technology to enable high-resolution, genome-wide assessment of all major types of structural variants.

De-risk induced pluripotent stel cell (iPSC) banks and other sources for allogeneic therapies with simple, NGS-based quality control of donor cells, seed banks, and post genome editing to ensure high-quality cell therapy products.

		Simultaneously detect all major types of structural variants and CNVs that could affect normal function our cause malignancies, on a genome-wide scale.
		Ensure the genomic integrity of iPSCs and other cell types.
		Reduce turnaround time and cost by characterizing the breadth of SVs and CNVs in a single, scalable NGS-based assay.

 

 

 

Get the complete picture with NGS and GPM

 

Automated analytics yield actionable results The CytoTerra® Platform provides a sample-to-report NGS-based cytogenetics assay that starts with a small number of cells from your cell therapy development process, and ends with a comprehensive and actionable report in standard and sequence-based nomenclature. Fully automated, cloud-based analysis of paired-end, short-read sequencing data is performed with Phase Genomics’ proprietary computational tools. The entire process can be completed in less than a week, and is scalable to large numbers of samples.